Yixin Kang
Changhongjie, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Myeloid sarcoma as EM blast crisis in BCR-ABL1 e6a2+ CML with myelofibrosis and TB: a case report.
Journal: Open life sciences
Published: May 28, 2026
Combination of Ceftazidime-Avibactam and Meropenem for the Treatment of Pneumonia and Bloodstream Infections Caused by Pan-Drug Resistant Pseudomonas aeruginosa ST244: A Case Report.
Journal: Infection and drug resistance
Published: October 17, 2025
Clinical risk factors, antimicrobial therapy, and virulence-associated mortality in patients with extensively drug-resistant or pan-drug-resistant (XDR/PDR) Pseudomonas aeruginosa pulmonary infections.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: September 10, 2025
The Role of blaOXA-101 and blaOXA-573 in Extensively Drug-Resistant/ Pan Drug-Resistant (XDR/PDR) Pseudomonas aeruginosa Resistance to Ceftazidime-Avibactam.
Journal: Infection and drug resistance
Published: December 16, 2024
Pharmacodynamic target attainment of the synergism of ceftazidime-avibactam in combination with amikacin against OXA-producing extensively drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa.
Journal: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
Published: August 26, 2024
Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa.
Journal: Frontiers in cellular and infection microbiology
Published: August 20, 2022
Evaluation of the Efficacy of Optimized Two-Step-Administration Therapy with Ceftazidime/Avibactam for Treating Extensively Drug-Resistant Pseudomonas aeruginosa Pulmonary Infections: a Pharmacokinetic/Pharmacodynamic Analysis.
Journal: Japanese journal of infectious diseases
Published: July 31, 2022
Compassionate Use of Contezolid for the Treatment of Tuberculous Pleurisy in a Patient with a Leadless Pacemaker.
Journal: Infection and drug resistance
Published: May 14, 2022
Pharmacokinetic/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in northern China.
Journal: Journal of global antimicrobial resistance
Published: March 31, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026